Wisonic Medical Completes Hundreds of Millions RMB Series B Funding Round Led by Shenzhen Capital Group and Hongtu Healthcare Fund

VCBeat has learned that Shenzhen Wisonic Medical Technology Co., Ltd. (“Wisonic Medical”) recently completed a Series B financing round worth hundreds of millions of yuan. The round was led by Shenzhen Capital Group Co., Ltd. (SCGC) and its affiliated Shenzhen Hongtu Medical Health Industry Equity Investment Fund Partnership (L.P.), with participation from Tianjin Teda Shenglin, Shenzhen High-Tech Investment Group, CICC Pucheng, and other institutions. The funds will be primarily used for the development and market launch of Wisonic Medical’s new products.

Wisonic Medical was established in March 2013. After eight years of development, it has grown into a Chinese national high-tech enterprise with fully independent intellectual property rights, integrating R&D, manufacturing, and marketing. Adhering to a user-centric approach, Wisonic Medical focuses on the application of clinical bedside devices in specialized sub-disciplines. Its core products and services include Next-Generation Ultrasound, Cloud Monitoring, Wisonic Cloud, and the 5G Ultrasound Air Clinic, delivering the value proposition of “Specialty-Specific Solutions” to users worldwide. In 2019Guangdong Cloud Intelligent Ultrasound Technology Engineering CenterEstablished with the support of Wisonic Medical! Wisonic Medical has successively established joint laboratories for cutting-edge technologies with prestigious universities such as Michigan State University, Tsinghua University, and Tongji University, as well as with multiple Grade A tertiary hospitals including Peking University Shenzhen Hospital, to foster industry-academia-research collaboration. Additionally, it has become a strategic partner in the 5G healthcare sector for leading companies such as China Mobile, China Unicom, and Tencent. Wisonic Medical is continuously innovating and growing into a new medical device enterprise centered on digital intelligence applications!

Li Yonggang, Chairman of Wisonic MedicalStatement: We extend our sincere gratitude to SCGC, Gaoxin Investment, and other institutions for their enduring trust and support in Wisonic Medical. Shenzhen Wisonic Medical Technology Co., Ltd. will remain steadfast in its user-centric development philosophy, focusing intently on customers, deepening its roots, drawing strength from uncertainty, and fostering robust corporate growth. We will continue to fulfill our mission of “enabling more people to share in exclusive life care,” firmly advance the development of “New Ultrasound,” promote the widespread adoption of precise, visualized point-of-care ultrasound technologies across various medical specialties, and empower physicians to uncover greater possibilities behind the images.

New Medical Devices—Data Intelligence: Precision and Efficiency, the Future Within Reach!

Yi Hongxiang, Partner of SCGC Hongtu Medical Health Industry FundStatement: Since its inception, the team at Shenzhen Wisonic Medical Technology Co., Ltd. has remained focused on niche clinical segments, adhering to a user-centric approach while leveraging cutting-edge 5G and AI technologies to continuously innovate and develop specialty-specific ultrasound products, thereby pioneering the "New Ultrasound" market segment. We believe that, amidst the rapidly evolving landscape of healthcare today, the Wisonic team is well-positioned to seize new opportunities in both niche sector development and global market expansion, achieving rapid growth and significant breakthroughs in addressing emerging needs, launching new products, and exploring new markets.

Liu Xin, Project Manager at Shenzhen High-Tech Investment GroupGaoxin Investment expressed optimism about Wisonic Medical’s product portfolio and market expansion in intelligent new ultrasound imaging systems, such as portable color Doppler ultrasound and specialty-specific color Doppler ultrasound. The company will advance the adoption of ultrasound visualization at the point of care to meet diagnostic needs across various clinical departments, thereby promoting precise disease prevention and treatment. With increasing penetration rates, the market potential is substantial. Gaoxin Investment will fully leverage its integrated insurance-investment model to provide comprehensive financing and investment support to Wisonic Medical, empowering innovators and facilitating the company’s faster and higher-quality development.

Shenzhen Capital Group Co., Ltd. is committed to its mission of discovering and empowering great enterprises, striving to be a discoverer and cultivator of innovative value. Since its establishment in 1999, SCGC has managed total assets exceeding RMB 400 billion, invested in more than 1,000 innovative high-tech companies, among which 186 have achieved public listings. Its portfolio spans industries such as information technology, internet, biotechnology/health, new energy/energy conservation and environmental protection, new materials, intelligent manufacturing, and consumer goods/modern services, covering the entire lifecycle of enterprises.

The SCGC Hongtu Medical Health Industry Fund, established in 2018, is the first medical health industry fund launched by Shenzhen Capital Group Co., Ltd. (SCGC) as part of its “specialization” strategy. The fund focuses on identifying high-quality targets with strong innovation capabilities and significant growth potential to drive industrial development. Within less than three years, the fund has invested in outstanding enterprises such as Akeso, YHLO, Medcaptain, Lianxin Medical, Ant Medical, Yuanhua Intelligence, Kangsheng Medical, Shanghai Zhimeng, GenFleet Therapeutics, and Leadcom.